olivLaw · US equity research
GE HealthCare Technologies Inc. GEHC
X-Ray Apparatus & Tubes & Related Irradiation Apparatus · SIC 3844 · Vertical: Instruments, medical and optical goods (SIC 384x)
GE HealthCare supplies medical imaging equipment, pharmaceutical diagnostic agents, patient monitoring solutions and AI-enabled software to hospitals and health systems worldwide. The company reported revenues of 20.6 billion dollars in fiscal 2025 and, in the second quarter of 2026, record orders, while its patient monitoring segment remains under pressure and tariffs continue to weigh on costs.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, GE HealthCare Technologies Inc. (GEHC) stock was 85.81 USD (+6.38% on the day), with market capitalisation 38.8 bn USD, P/E 18.1 on diluted EPS of 4.74 USD over the last 12 months, dividend yield 0.17%, beta 1.09, 52-week range 59.49–88.16 USD. Latest reported quarter (Q3 2026): revenue of 5.5 bn USD (+7.2% YoY), net income of 615.0 m USD (+37.9% YoY), diluted EPS 1.36 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 85.2
- overbought (≥ 70)
- Bollinger (20, 2)
- 61.80 – 82.67
- above the upper band · %B 1.15 · band width 28.9%
- SMA 50 / 200
- 68.91 / 69.83
- mixed trend
- MACD (12, 26, 9)
- 3.67 / 2.25
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +30.5% | −1.1% | +31.6 pp | — |
| 3 months | +22.2% | −0.5% | +22.6 pp | — |
| 6 months | +39.0% | +4.4% | +34.6 pp | — |
| Year to date | +4.6% | +12.3% | −7.7 pp | — |
| 1 year | +15.5% | +13.5% | +1.9 pp | +6.2% |
| 3 years | +19.9% | +76.4% | −56.5 pp | +20.0% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.3 bn | 4.8 bn | 5.0 bn | 5.1 bn | 5.7 bn | 5.1 bn | 5.3 bn | 5.5 bn |
| Gross profit | 2.3 bn | 2.0 bn | 2.0 bn | 2.0 bn | 2.3 bn | 2.0 bn | 2.2 bn | 2.2 bn |
| Research & development | 344.0 m | 344.0 m | 302.0 m | 292.0 m | 323.0 m | 345.0 m | 323.0 m | 320.0 m |
| SG&A | 1.1 bn | 1.0 bn | 1.0 bn | 1.0 bn | 1.1 bn | 1.1 bn | 1.1 bn | 1.1 bn |
| Operating income | 801.0 m | 629.0 m | 654.0 m | 653.0 m | 827.0 m | 515.0 m | 739.0 m | 805.0 m |
| Interest expense | 121.0 m | 110.0 m | 113.0 m | 111.0 m | 105.0 m | 96.0 m | 114.0 m | 122.0 m |
| Pre-tax income | 834.0 m | 692.0 m | 613.0 m | 643.0 m | 821.0 m | 505.0 m | 693.0 m | 752.0 m |
| Income tax | 96.0 m | 104.0 m | 113.0 m | 179.0 m | 219.0 m | 94.0 m | 119.0 m | 129.0 m |
| Net income | 721.0 m | 564.0 m | 486.0 m | 446.0 m | 589.0 m | 389.0 m | 561.0 m | 615.0 m |
| Diluted EPS | 1.57 ≈ | 1.23 | 1.06 | 0.98 | 1.29 ≈ | 0.85 | 1.24 | 1.36 |
| Operating cash flow | — | 250.0 m | 94.0 m ≈ | 593.0 m ≈ | — | 290.0 m | 168.0 m ≈ | 907.0 m ≈ |
| Capex | 102.0 m | 152.0 m | 86.0 m ≈ | 110.0 m ≈ | 134.0 m | 178.0 m | 100.0 m ≈ | 114.0 m ≈ |
| Dividends paid | 14.0 m | 16.0 m | 16.0 m ≈ | 16.0 m ≈ | 16.0 m | 16.0 m | 16.0 m ≈ | 16.0 m ≈ |
| Share repurchases | 0 | 0 | 100.0 m ≈ | 100.0 m ≈ | 0 | 100.0 m | 200.0 m ≈ | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 56 percentile of its own 16-quarter history (min 13.8, median 18.0, max 26.6; quarters with earnings only).
Fiscal years
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 17.6 bn | 18.3 bn | 19.6 bn | 19.7 bn | 20.6 bn |
| Revenue YoY | unavailable | +4.3% | +6.6% | +0.6% | +4.8% |
| Net income | 2.2 bn | 1.9 bn | 1.6 bn | 2.0 bn | 2.1 bn |
| Net income YoY | unavailable | −14.7% | −18.2% | +27.1% | +4.6% |
| Diluted EPS | 4.95 | 4.22 | 3.03 | 4.34 | 4.55 |
| Diluted EPS YoY | unavailable | −14.7% | −28.2% | +43.2% | +4.8% |
| net % | 12.8% | 10.4% | 8.0% | 10.1% | 10.1% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 4.5 bn USD
- Financial debt
- 10.0 bn USD
- Net debt
- 5.5 bn USD
- Equity
- 10.4 bn USD
- Total assets
- 36.9 bn USD
- Debt / equity
- 0.96x
- Current ratio
- 1.37x
- ROE
- 22.1%
- ROA
- 6.0%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Revenue | 17.6 bn | 18.3 bn | 19.6 bn | 19.7 bn | 20.6 bn | SEC (XBRL)· 04 Feb 2026verified |
| Gross profit | 7.2 bn | 7.2 bn | 7.9 bn | 8.2 bn | 8.2 bn | SEC (XBRL)· 04 Feb 2026verified |
| Research & development | 816.0 m | 1.0 bn | 1.2 bn | 1.3 bn | 1.3 bn | SEC (XBRL)· 04 Feb 2026verified |
| SG&A | 3.6 bn | 3.6 bn | 4.3 bn | 4.3 bn | 4.2 bn | SEC (XBRL)· 04 Feb 2026verified |
| Operating income | 2.8 bn | 2.5 bn | 2.4 bn | 2.6 bn | 2.8 bn | SEC (XBRL)· 04 Feb 2026verified |
| Interest expense | 40.0 m | 77.0 m | 542.0 m | 504.0 m | 440.0 m | SEC (XBRL)· 04 Feb 2026verified |
| Pre-tax income | 2.9 bn | 2.5 bn | 2.4 bn | 2.6 bn | 2.8 bn | SEC (XBRL)· 04 Feb 2026verified |
| Income tax | 600.0 m | 563.0 m | 743.0 m | 531.0 m | 614.0 m | SEC (XBRL)· 04 Feb 2026verified |
| Net income | 2.2 bn | 1.9 bn | 1.6 bn | 2.0 bn | 2.1 bn | SEC (XBRL)· 04 Feb 2026verified |
| Diluted EPS | 4.95 | 4.22 | 3.03 | 4.34 | 4.55 | SEC (XBRL)· 04 Feb 2026verified |
| Weighted average diluted shares | 454.0 m | 454.0 m | 458.0 m | 459.0 m | 458.0 m | SEC (XBRL)· 04 Feb 2026verified |
| Dividend per share | — | — | 0.12 | 0.13 | 0.14 | SEC (XBRL)· 04 Feb 2026verified |
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Cash | 561.0 m | 1.4 bn | 2.5 bn | 2.9 bn | 4.5 bn | SEC (XBRL)· 04 Feb 2026verified |
| Inventories | — | 2.2 bn | 2.0 bn | 1.9 bn | 2.2 bn | SEC (XBRL)· 04 Feb 2026verified |
| Current assets | — | 8.3 bn | 9.4 bn | 9.9 bn | 12.5 bn | SEC (XBRL)· 04 Feb 2026verified |
| Property, plant & equipment, net | — | 2.0 bn | 2.1 bn | — | — | SEC (XBRL)· 06 Feb 2024verified |
| Goodwill | 12.9 bn | 12.8 bn | 12.9 bn | 13.1 bn | 13.5 bn | SEC (XBRL)· 04 Feb 2026verified |
| Intangibles (excl. goodwill) | — | 1.5 bn | 1.3 bn | 1.1 bn | 1.1 bn | SEC (XBRL)· 04 Feb 2026verified |
| Total assets | — | 27.5 bn | 32.5 bn | 33.1 bn | 36.9 bn | SEC (XBRL)· 04 Feb 2026verified |
| Accounts payable | — | 2.9 bn | 2.9 bn | 3.0 bn | 3.3 bn | SEC (XBRL)· 04 Feb 2026verified |
| Short-term debt | — | 15.0 m | 1.0 bn | 1.5 bn | 508.0 m | SEC (XBRL)· 04 Feb 2026verified |
| Long-term debt | — | 8.2 bn | 8.4 bn | 7.4 bn | 9.5 bn | SEC (XBRL)· 04 Feb 2026verified |
| Current liabilities | — | 7.2 bn | 9.0 bn | 9.6 bn | 9.1 bn | SEC (XBRL)· 04 Feb 2026verified |
| Total liabilities | — | 17.9 bn | 25.1 bn | 24.4 bn | 26.3 bn | SEC (XBRL)· 04 Feb 2026verified |
| Equity | 16.7 bn | 9.4 bn | 7.1 bn | 8.5 bn | 10.4 bn | SEC (XBRL)· 04 Feb 2026verified |
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Capex | 248.0 m | 310.0 m | 387.0 m | 401.0 m | 482.0 m | SEC (XBRL)· 04 Feb 2026verified |
| Investing cash flow | -1.8 bn | -398.0 m | -558.0 m | -914.0 m | -1.0 bn | SEC (XBRL)· 04 Feb 2026verified |
| Financing cash flow | -263.0 m | -822.0 m | -478.0 m | -573.0 m | 617.0 m | SEC (XBRL)· 04 Feb 2026verified |
| Dividends paid | 0 | 0 | 41.0 m | 55.0 m | 64.0 m | SEC (XBRL)· 04 Feb 2026verified |
| Share repurchases | — | — | 0 | 0 | 200.0 m | SEC (XBRL)· 04 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 49 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 38.8 bn USD
Key indicators
Coverage and freshness
Score by group
- Balance sheet64
- Valuation100
- Quality44
- Growth25
- Returns13
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 129.51 – 229.61 USD.
Methods computed but outside the aggregate range: Dividend discount (DDM) (a small share of earnings is paid as dividends (capital returns through buybacks): the dividend model does not describe the value and stays outside the aggregate).
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E129.51 – 229.61 (Mid 153.58)12 companies used · median multiple 32.4x · quartiles 27.3x – 48.5xBDX, BSX, DXCM, EW, ISRG, MDT, MMM, RMD, STE, SYK, WST, ZBH
- Dividend discount (DDM)outside the aggregate1.84 – 2.47 (Mid 2.11)a small share of earnings is paid as dividends (capital returns through buybacks): the dividend model does not describe the value and stays outside the aggregate
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 49/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 13.1% | 60 (vs peers) | 17% |
| Net margin · Quality | 10.0% | 17 (vs peers) | 10% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 4.0% | 33 (on a fixed band) | 14% |
| EPS CAGR 3Y · Growth | 2.5% | 17 (on a fixed band) | 14% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 6.6x | 79 (on a fixed band) | 10% |
| Current ratio · Balance sheet | 1.3x | 42 (on a fixed band) | 7% |
| P/E (TTM) · Valuation | 18.1x | 100 (vs peers) | 17% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | 0.9% | 13 (on a fixed band) | 10% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet64/100 · 2/3 factors with a value
- Growth25/100 · 2/2 factors with a value
- Quality44/100 · 2/3 factors with a value
- Returns· partial13/100 · 1/2 factors with a value
- Valuation· partial100/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
GE HEALTHCARE TECHNOLOGIES INC. (GEHC). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 20.6 bn USD in 2025; YoY growth 4.8%; net margin 10.0%; ROE 19.9%.
The estimated value range is 129.51–229.61 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 153.58 USD, the price of 85.81 USD leaves a potential of 79.0% (value / price − 1) and a margin of safety of 44.1% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 49/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns, valuation. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Interest coverage: 6.6x
- P/E (TTM): 18.1x
- The price is below the estimated value range
What contradicts it
- Net margin: 10.0%
- EPS CAGR 3Y: 2.5%
- Shareholder yield (distributions): 0.9%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Net debt / EBITDA, EV/EBITDA, FCF yield, Payout ratio (FCF).
Versus the vertical median
Instruments, medical and optical goods (SIC 384x) · same industry group (3-digit SIC) · compared with 12 companies
Only companies with a capitalisation between 4.1 bn and 259.9 bn (within 8× of the company's); 156 of the vertical were left out.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ISRGIntuitive Surgical, Inc. | 167.1 bn | 58.3 | 18.0% | 25.5% | +20.5% | −16% / +55% |
| MDTMedtronic plc | 134.3 bn | 25.8 | 10.7% | 13.9% | +8.4% | −0% / +32% |
| SYKStryker Corp | 129.3 bn | 36.2 | 16.0% | 13.8% | +11.2% | −8% / +15% |
| MMM3m Company | 100.2 bn | 28.9 | 80.8% | 14.0% | +1.5% | +13% / +134% |
| BSXBoston Scientific Corporation | 66.4 bn | 19.4 | 14.3% | 16.6% | +19.9% | −55% / −18% |
| EWEdwards Lifesciences Corporation | 57.1 bn | 56.2 | 9.7% | 15.3% | +11.5% | +15% / +47% |
| BDXBecton, Dickinson And Company | 57.0 bn | 63.2 | 3.8% | 4.0% | +8.2% | +37% / +13% |
| GEHCGe Healthcare Technologies Inc. | 38.8 bn | 18.1 | 19.9% | 10.0% | +4.8% | +15% / +20% |
| RMDResMed Inc. | 33.8 bn | 21.9 | 26.4% | 27.8% | +9.9% | −6% / +52% |
| DXCMDexcom, Inc. | 33.0 bn | 34.8 | 37.7% | 19.4% | +15.6% | +39% / −23% |
| WSTWest Pharmaceutical Services, Inc. | 28.5 bn | 45.9 | 21.2% | 18.8% | +6.3% | +47% / +17% |
| STESTERIS plc | 24.2 bn | 30.0 | 11.4% | 13.3% | +8.7% | −7% / +23% |
| ZBHZimmer Biomet Holdings, Inc. | 20.8 bn | 27.9 | 6.0% | 9.0% | +7.2% | +13% / −5% |
1- and 3-year price returns: for GEHC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 50.76 Total return -41% · Per year -41% | 89.76 Total return 5% · Per year 5% | 135.24 Total return 58% · Per year 58% |
| 3 years | 48.76 Total return -43% · Per year -17% | 97.07 Total return 14% · Per year 4% | 160.64 Total return 88% · Per year 23% |
| 5 years | 46.84 Total return -45% · Per year -11% | 104.97 Total return 23% · Per year 4% | 190.82 Total return 124% · Per year 17% |
- Exit P/E± 24.27
- Net margin± 16.99
- Annual revenue growth± 14.01
- Annual dilution± 1.43
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (28 Oct 2026 · results), 10-Q (28 Oct 2026).
In brief
GE HealthCare supplies medical imaging equipment, pharmaceutical diagnostic agents, patient monitoring solutions and AI-enabled software to hospitals and health systems worldwide. The company reported revenues of 20.6 billion dollars in fiscal 2025 and, in the second quarter of 2026, record orders, while its patient monitoring segment remains under pressure and tariffs continue to weigh on costs.
SWOT
Strengths
Weaknesses
- Patient Care Solutions is shrinking and loss-making, which weighs on overall results 3.
- Margins are under pressure from production costs and tariffs, and the company does not expect mitigation to fully offset the impact 12.
- Financial debt is significant, which limits flexibility in case of economic shocks 2.
Opportunities
- Growing demand for nuclear medicine and radiopharmaceuticals could support the pharmaceutical segment over the long term 3.
- AI-enabled software and cloud solutions can generate recurring revenue and expand addressable markets 13.
- Tariff refunds recognized in 2026 could improve profitability if recoveries are confirmed 23.
Risks
- Tariffs and international tradehigh
Tariffs imposed by the United States and other countries could continue to weigh on profitability, and mitigation actions are not expected to fully offset the costs 12.
- Competition in Chinahigh
Local companies and volume based procurement could reduce orders and revenue in this region 12.
- Patient Care Solutionsmedium
Revenue decline and losses in this segment could persist if recovery does not materialize, and management is reviewing strategic options 3.
- Component cost inflationmedium
Costs for memory chips, oil and freight could exceed current estimates 3.
- Debt and pension obligationslow
Financial debt and postretirement obligations could limit financial flexibility if actual costs exceed estimates 12.
Investment thesis
What would need to be true (bull case)
- Record orders and backlog point to solid demand, and the Pharmaceutical Diagnostics and Advanced Imaging Solutions segments are growing well 3.
- The reaffirmed 2026 guidance suggests management expects earnings per share growth through the year 3.
- The combined portfolio of equipment, software and pharmaceutical agents could generate recurring revenue and a strong position in personalized medicine 1.
What would break the thesis
- Tariffs and component costs have reduced margins, and recovery of tariff refunds remains uncertain 23.
- Patient monitoring is shrinking and loss-making, which could weigh on overall performance if it does not recover 3.
- Competition in China and geopolitical pressures could limit growth in important regions for the company 12.
What to watch
- Decision on strategic options for Patient Care Solutions2026
- Final amount of IEEPA tariff refunds and any further recoveries2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (28 Oct 2026 · results), 10-Q (28 Oct 2026).
The business
GE HealthCare Technologies Inc., headquartered in Chicago, was spun off from General Electric on January 3, 2023, and in fiscal 2025 operated four reportable segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics 1. Revenue comes from medical devices, consumables, services and cloud and AI-enabled software, with customers including hospitals, health systems and research institutions 1. The company says its revenues, operating profits and cash flows vary from quarter to quarter, with the fourth quarter historically the strongest 1.
Trends
- Tariffsmixed
Tariffs imposed by the United States and other countries reduced operating income and cash flows, and in 2026 the company recognized refunds of tariffs under IEEPA. Recovery depends on administrative processing and legal developments, so the final effect remains uncertain 23.
- Demand for advanced solutionstailwind
Organic orders grew 11.1% in the second quarter of 2026 and the book-to-bill ratio was 1.15, which points to solid demand for new equipment and solutions 3.
- Pressure in Chinaheadwind
Volume based procurement and competition from local companies have reduced orders and revenue in China, and this could continue 12. The company says local investments could help over the long term.
Competitive position
The company names Siemens Healthineers, Philips Healthcare, United Imaging, Mindray and Canon as primary global competitors, and in pharmaceutical diagnostics it competes with Bayer, Bracco, Guerbet and Curium 1. Competition centers on value, quality, safety, delivery speed, service, innovation and brand reputation 1.
Pressure also comes from independent service organizations seeking access to original manufacturer tools and parts, and right-to-repair legislation could strengthen their position 1. The company also faces local competitors in China that can offer lower prices 12.
- Siemens Healthineers
Global competitor in imaging and medical equipment, named as a primary competitor in the annual report.
- Philips Healthcare
Global competitor in imaging and monitoring, named as a primary competitor.
- United Imaging
Regional manufacturer gaining share, especially in China, named in the report.
- Bracco
Competitor in contrast diagnostic agents, named in the pharmaceutical segment discussion.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Buy the dip on GE Healthcare, says NeedhamCNBC — Top News · 22 Sept 2026 · EN
- GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal. What Would Ownership Add?Yahoo Finance — News · 17 Sept 2026 · EN
- GE HealthCare’s (GEHC) Latest Scanner Breakthrough Meets A Mixed MarketYahoo Finance — News · 02 Sept 2026 · EN
- GE HealthCare ajunge la aproape 20.000 de sisteme medicale instalate în România, după 25 de ani pe piaţa localăZiarul Financiar · 28 May 2026 · RO
The latest news item in our archive is from 22 Sept 2026; the newest SEC filing is from 28 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report28 Oct 2026
- Current report28 Oct 2026Results of operations · Departure or appointment of officers · Financial statements and exhibits
- Current report22 Sept 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report18 Aug 2026Departure or appointment of officers · Financial statements and exhibits
- Current report29 Jul 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report29 Jul 2026
- Current report29 Jul 2026Results of operations · Financial statements and exhibits
- Current report23 Jul 2026Results of operations · Departure or appointment of officers · Financial statements and exhibits
- Current report11 May 2026Shareholder vote · Other events
- Quarterly report29 Apr 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / GE HealthCare Technologies Inc. · 04 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / GE HealthCare Technologies Inc. · 29 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / GE HealthCare Technologies Inc. · 29 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.